← All trials
NCT07263607
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2026
- Primary completion
- Jul 31, 2029
- Completion date
- Nov 30, 2029
- First posted
- Dec 4, 2025
- Last posted
- Dec 4, 2025
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan UniversityLead sponsor
- North Sichuan Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Chongqing Medical UniversityCollaborator
- Kunming Medical UniversityCollaborator
- LanZhou UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- People's Liberation Army of ChinaCollaborator
- Inner Mongolia Medical UniversityCollaborator
- People's Hospital of LeshanCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.